<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184713</url>
  </required_header>
  <id_info>
    <org_study_id>HULP 5358</org_study_id>
    <nct_id>NCT04184713</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of an Specific Oral Nutritional Supplement on the Nutritional Status in Cancer and Malnutrition</brief_title>
  <official_title>A Clinical Trial With Nutritional Intervention to Evaluate the Effect of an Specific Oral Nutritional Supplement on the Nutritional Status in Patients With Cancer and Malnutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adventia Pharma, S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of a specific nutritional oral supplement on the nutritional status of patients with&#xD;
      cancer and malnutrition&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentric, parallel, randomized, double blind and controlled clinical-nutritional study of&#xD;
      8 weeks of duration and 2 study groups of treatment: Experimental group (experimental&#xD;
      nutritional oral supplement); and Control group (control nutritional oral supplement) to&#xD;
      evaluate the effect on the nutritional and functional status, the quality of life and body&#xD;
      composition of patients with cancer and malnutrition undergoint specficic treatment&#xD;
      (chemotherapy, radiotherapy, inmunotherapy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Change from baseline to day 142</time_frame>
    <description>Subjective Global Assessment (SGA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diet quality</measure>
    <time_frame>Change from baseline to day 142</time_frame>
    <description>72h food registry questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status</measure>
    <time_frame>Change from baseline to day 142</time_frame>
    <description>Dinamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group Scale (ECOG)</measure>
    <time_frame>Change from baseline to day 142</time_frame>
    <description>Eastern Cooperative Oncology Group Scale (ECOG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Change from baseline to day 142</time_frame>
    <description>BIA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Malnutrition</condition>
  <condition>Cancer</condition>
  <condition>Nutrition Related Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Experimental Group</intervention_name>
    <description>Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women over 18 with a cancer diagnosis (any type).&#xD;
&#xD;
          -  Subjects who have initiated during the next mont a treatment with chemo and or&#xD;
             radiotherapy with or without surgery.&#xD;
&#xD;
          -  Having lost more than 5% of body weight in the last 6 months.&#xD;
&#xD;
          -  Adequate cultural level and understanding for the clinical trial.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are participating in other clinical trials.&#xD;
&#xD;
          -  Subjects with morbid obesity.&#xD;
&#xD;
          -  Subjects who will undergo surgery or who will undergo.&#xD;
&#xD;
          -  Subjects with cachexia&#xD;
&#xD;
          -  Subjects with infection of a cause other than of the tumor&#xD;
&#xD;
          -  Subjects with an infectious process&#xD;
&#xD;
          -  Subjects with Diabetes Mellitus treated with insulin and/or not controlled&#xD;
&#xD;
          -  Subjects with kidney, heart, respiratory or liver disease.&#xD;
&#xD;
          -  Subjects with autoimmune diseases.&#xD;
&#xD;
          -  Subjects with mental illness or decrease function cognitive.&#xD;
&#xD;
          -  Subjects who consume oral supplements or artificial nutrition and who cannot be&#xD;
             withdran at least 1 week before startint the study.&#xD;
&#xD;
          -  Patients who have consumed food supplements or fortified foods in omega 3 (arginine or&#xD;
             nucleotides) during the previous month.&#xD;
&#xD;
          -  Patients who reject oral supplements.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Allergic to any component of the formula&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Gómez Candela, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Health Research IdiPAZ</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>July 18, 2021</last_update_submitted>
  <last_update_submitted_qc>July 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malnutrition</keyword>
  <keyword>cancer</keyword>
  <keyword>nutrition</keyword>
  <keyword>nutritional oral supplement</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

